Yahoo · Sep 9, 2026
Prothena to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
DUBLIN, Ireland, September 09, 2026--Prothena to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
PR
NASDAQ · PRTA
Prothena Corporation plc Ordinary Shares
Healthcare · Biotechnology
$8.02
Down-$0.25 (-3.02%)
Updated Oct 7, 2026, 2:22 AM
SID Score
3.6/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 556.49M
- P/E ratio
- -1.98
- Dividend yield
- 0.00%
- 52-week range
- $7.73 – $11.80
- Volume
- 510.61K
- Avg. volume
- 643.8K
Price performance · PRTA
PRTA price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 6, 2026
PRTA closed at $8.02 after 21 trading sessions, down 15.93% for the selected period.
- Last close
- $8.02
- Period change
- -15.93%
- Period low
- $8.02
- Period high
- $9.54
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 6, 2026 | $8.28 | $8.28 | $7.80 | $8.02 | 510.61K |
| Oct 5, 2026 | $8.335 | $8.37 | $7.91 | $8.27 | 714.46K |
| Oct 2, 2026 | $8.62 | $8.62 | $8.35 | $8.36 | 675.84K |
| Oct 1, 2026 | $8.54 | $8.58 | $8.35 | $8.54 | 457.09K |
| Sep 30, 2026 | $8.98 | $8.99 | $8.365 | $8.38 | 634.78K |
| Sep 29, 2026 | $8.66 | $8.80 | $8.59 | $8.78 | 602.98K |
| Sep 28, 2026 | $8.25 | $8.86 | $8.0733 | $8.72 | 488.86K |
| Sep 25, 2026 | $8.38 | $8.52 | $8.185 | $8.29 | 481.05K |
| Sep 24, 2026 | $8.63 | $8.73 | $8.28 | $8.32 | 426.06K |
| Sep 23, 2026 | $8.94 | $8.97 | $8.665 | $8.68 | 357.84K |
| Sep 22, 2026 | $8.72 | $9.09 | $8.70 | $8.99 | 445.5K |
| Sep 21, 2026 | $8.59 | $8.795 | $8.46 | $8.51 | 363.16K |
| Sep 18, 2026 | $8.41 | $8.60 | $8.25 | $8.58 | 1.83M |
| Sep 17, 2026 | $8.39 | $8.56 | $8.23 | $8.46 | 404.76K |
| Sep 16, 2026 | $8.35 | $8.50 | $8.20 | $8.24 | 398.34K |
| Sep 15, 2026 | $8.86 | $8.86 | $8.295 | $8.33 | 323.44K |
| Sep 14, 2026 | $8.95 | $8.99 | $8.79 | $8.86 | 374.87K |
| Sep 11, 2026 | $9.06 | $9.14 | $8.765 | $8.93 | 376.28K |
| Sep 10, 2026 | $9.25 | $9.255 | $8.97 | $9.02 | 310.91K |
| Sep 9, 2026 | $9.40 | $9.4958 | $9.22 | $9.30 | 294.56K |
| Sep 8, 2026 | $9.60 | $9.67 | $9.345 | $9.54 | 305.44K |
Latest PRTA news
The latest Smart Investors Daily articles mentioning PRTA.
Stock researchCompany · Overview
Company
Market Activity
Research & News
PRTA research
Overview
Company profile and research snapshot.
Company profile
Prothena Corp PLC is a clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including ATTR amyloidosis [Coramitug (PRX004)], Alzheimer's disease (PRX123), Neurodegeneration (PRXPRX019), and Others.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $26.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| May 8, 2026 | Citizens | Market Outperform | — |
| Feb 20, 2026 | RBC Capital | Sector Perform | — |
| Dec 1, 2025 | Citizens | Market Outperform | — |
| Nov 7, 2025 | HC Wainwright & Co. | Buy | — |
| Nov 7, 2025 | RBC Capital | Sector Perform | — |
News briefing
No generated briefing is available yet.
Yahoo · Aug 14, 2026
KMDA or PRTA: Which Is the Better Value Stock Right Now?
KMDA vs. PRTA: Which Stock Is the Better Value Option?
Yahoo · Aug 7, 2026
PRTA's Q2 Loss Narrower Than Expected, Pipeline Progress in Focus
Prothena beat adjusted Q2 loss estimates, reaffirmed 2026 cash-use guidance and highlights partner pipeline progress as a key milestone decision nears.
Benzinga · Aug 7, 2026
CORRECTION: Prothena Corp Q2 EPS $(0.36) Misses $(0.09) Estimate, Sales $1.010M Miss $28.295M Estimate
Prothena Corp (NASDAQ:PRTA) reported quarterly losses of $(0.36) per share which missed the analyst consensus estimate of $(0.09) by 300 percent. This is a 79.19 percent increase over losses of $(1.73) per share from
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
